Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | RET C634Y |
Gene Variant Detail | |
Relevant Treatment Approaches | RET Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
RET C634Y | Advanced Solid Tumor | sensitive | RET Inhibitor | Ponatinib | Preclinical | Actionable | In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells harboring RET C634Y in culture (PMID: 23526464). | 23526464 |
RET C634Y | Advanced Solid Tumor | sensitive | RET Inhibitor | HG-6-63-01 | Preclinical | Actionable | In a preclinical study, HG-6-63-01 inhibited RET phosphorylation and downstream signaling and reduced proliferation of transformed cells expressing RET C634Y in culture (PMID: 26046350). | 26046350 |
RET C634Y | Advanced Solid Tumor | sensitive | RET Inhibitor | XMD15-44 | Preclinical | Actionable | In a preclinical study, XMD15-44 inhibited RET phosphorylation and downstream signaling and reduced proliferation of transformed cells expressing RET C634Y in culture (PMID: 26046350). | 26046350 |
RET C634Y | Advanced Solid Tumor | sensitive | RET Inhibitor | ALW-II-41-27 | Preclinical - Cell culture | Actionable | In a preclinical study, ALW-II-41-27 inhibited RET phosphorylation and downstream signaling, reduced proliferation of transformed cells expressing RET C634Y in culture (PMID: 26046350). | 26046350 |
RET C634Y | medullary thyroid carcinoma | predicted - sensitive | RET Inhibitor | Sorafenib | Case Reports/Case Series | Actionable | In a Phase II trial, Nexavar (sorafenib) treatment resulted in stable disease in one patient with medullary thyroid carcinoma harboring RET C634Y (PMID: 20368568; NCT00390325). | 20368568 |